MutS Homolog 2 (MSH2) is a protein involved in the mismatch-repair pathway. This protein is commonly associated with hereditary non-polyposis colorectal cancer, and mutations in this gene are correlated with the development of sporadic colorectal carcinoma. Expression levels of MSH2 are abnormally low in a high percentage of patients with microsatellite instability, as well as endometrial and ovarian cancers. Use of Anti-MSH2 is optimized when paired in an IHC panel with antibodies against MSH6, MLH1, and PMS2. Reports have shown Anti-MSH2 to be useful in the detection of the protein in a number of normal and neoplastic tissues, and for identifying a loss of MSH2 in tumors that are microsatellite-unstable.

Pal T, et al. Cancer. 2008; 113:733-42. Brueckl WM, et al. Anticancer Res. 2003; 23:1773-8. Rigau V, et al. Arch Pathol Lab Med. 2003; 127:694-700. Renkonen E, et al. J Clin Oncol. 2003; 21:3629-37. Hoedema R, et al. Am Surg. 2003; 69:387-92. Christensen M, et al. Cancer. 2002; 95:2422-30. Wahlberg SS, et al. Cancer Res. 2002; 62:3485-92. Lanza G, et al. Mod Pathol. 2002; 15:741-9. Thibodeau SN, et al. Cancer Res 1996; 56:4836-40.